N/A
N=3,830
Seroepidemiological Study of Pertussis and Other Infectious Diseases
Pertussis Infection
Bottom Line
View on ClinicalTrials.gov: NCT01929473 ↗Enrolled (actual)
3,830
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcome: Primary: IgG — 1.254; 1.258 EU/mL(log transformed)
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- Gifu Prefecture Medical Association
- Primary completion
- Nov 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY IgG |
1.254; 1.258 | — |
| SECONDARY Incidence of Pertussis |
— | — |
| SECONDARY Antibodies of Varicella, Mumps and Rubella |
— | — |
| SECONDARY Infection Risk Factors Including Family Numbers, Living Space, With or Without a Cough Patient in the Surroundings, Medical History and Hospitalization |
— | — |
Summary
Serum samples will be corrected twice from the same youth subjects with one year interval.
Seroincidence of pertussis will be estimated by the elevation of Ig-G-PT in paired sera from an identical individual.
The relationship between the incidence and the demographic data or medical history of the subjects will be discussed.
Eligibility Criteria
Inclusion Criteria
- Students of junior high school, high schools or college in Gifu prefecture
- Students who can have the second blood drawing one year later
- Students (and their parent when students are underage) whose written consent is obtainable.
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01929473). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.